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ARTHRITIS—Clinical Outcomes Studies
PAR1
GLUCOSAMINEVS PLACEBO INTHETREATMENT OF
OSTEOARTHRITIS: META-ANALYSIS
O’Leary BA1, Glase KM1,Adena M2, Hutchinson RS2
1Covance Pty Ltd, Sydney, NSW, Australia, 2Covance Pty Ltd,
Canberra, ACT, Australia
OBJECTIVES: To determine the efﬁcacy of glucosamine by con-
ducting a meta-analysis of double blinded, randomised, con-
trolled trials (RCTs) comparing glucosamine with placebo.
METHODS: Published RCTs were identiﬁed from the Cochrane
review and a literature search of Medline, Embase and the
Cochrane Clinical Trials Register. The outcomes examined were
change in mean and minimum joint space narrowing (JSN),
WOMAC (Western Ontario and McMaster Universities Arthritis
Index) (pain, function and stiffness and total) and the Lequesne
Index. The WOMAC scales were adjusted to a common scale.
Key exclusion criteria were: non-oral administration, no out-
comes of interest, <20 patients and non-English publication. The
ten studies comprised seven using glucosamine sulphate, two,
glucosamine hydrochloride, and one, salt not stated. Duration of
followup was <=2 weeks in ﬁve studies, 12–26 weeks in three
studies and three years in two studies. Where possible, the data
were analysed on an intent-to-treat basis. Usually, this involved
extrapolating missing data, as would occur for patients who
discontinued from the trial, by using the last valid value for that
patient. RESULTS: The estimates (95% conﬁdence interval,
p-value) of the random-effects meta-analysis of glucosamine vs
placebo were: JSN mean, mm (2 studies): 0.24 (0.11, 0.36),
0.0001; JSN minimum, mm (1 study): 0.33 (0.11, 0.55), 0.003;
WOMAC total (7 studies): -2.05 (-3.72, -0.38), 0.02; WOMAC
pain (7 studies): -0.36 (-0.84, 0.12), 0.14; WOMAC function (7
studies): -1.72 (-2.95, -0.50), 0.006; WOMAC stiffness (6
studies): -0.09 (-0.28, 0.10), 0.36; Lequesne Index (5 studies):
-2.02 (-3.18, -0.85), 0.0007. Glucosamine was statistically sig-
niﬁcantly better than placebo for JSN, total WOMAC and func-
tion subscale and the Lequesne Index. Similar results for
WOMAC pain and stiffness subscales did not reach statistical
signiﬁcance. CONCLUSION: The meta-analysis indicates that
glucosamine improves outcomes in osteoarthritis.
PAR2
DOES RACE INFLUENCE A PATIENT’S LIKELIHOOD OF BEING
PRESCRIBED SELECTIVE CYCLOOXYGENASE-2 INHIBITORS
(COX-2S) VERSUS OTHER NONSTEROIDAL
ANTI-INFLAMMATORY AGENTS (NSAIDS) IN MEDICAID
MANAGED CARE PLANS (MCOS)?
Neild A1, Cuffel B2
1PPSI, Stamford, CT, USA, 2Harvard U, Boston, MA, USA
OBJECTIVES: To determine whether race inﬂuences a patient’s
likelihood of being prescribed selective cyclooxygenase-2 inhi-
bitors (COX-2s) versus other nonsteroidal anti-inﬂammatory
agents (NSAIDs) in Medicaid managed care plans (MCOs).
METHODS: All medical and prescription claims for MCO
enrollees receiving at least one prescription for a COX-2 or
NSAID between January 2000 and June 2002 were retrieved.
Selected for study were adults claiming at least one COX-2
prescription or NSAID prescription with a minimum 30 days
supply after June 2000; having 60 total days of supply or more
over the study period was also required for study inclusion. The
probability of being a COX-2 user was estimated as a logistic
function of patient age, gender, race, city/suburban/rural resi-
dence, and history of rheumatoid arthritis, osteoarthritis, chronic
back pain, acute pains, gastrointestinal problems, and comor-
bidities (hypertension, hyperlipidemia, obesity, diabetes, renal
problems, alcohol/tobacco/drug abuse, cardiovascular events).
RESULTS: Sample COX-2 users numbered 4349 and NSAID
users numbered 13,489. Half were African-American, three-
quarters were female, and a third was over 50 years old. After
adjusting for confounders, African-American and other races
were a third less likely to be COX-2 users than Caucasians (OR,
0.66; 95% CI, 0.61–0.72). Residence in Baltimore was an addi-
tional factor reducing COX-2 usage (OR, 0.87; 95%CI, 0.80–
0.95). Gender was not a signiﬁcant factor. Age and all clinical
covariates but diabetes was signiﬁcant predictors at the 0.05
level. CONCLUSION: Race signiﬁcantly affected access to
COX-2 medication in Medicaid MCOs, even after adjusting for
other demographic and clinical variables. Cost to the patient
was not a factor, as the patient co-payment was $1 for any
prescription.
ARTHRITIS—Cost Studies
PAR3
COST-BENEFIT OF RITUXIMAB FOR RHEUMATOID ARTHRITIS
PATIENTS IN ARGENTINA
Solé JP1, Ortega GP1, Kielhorn A2
1Productos Roche S.A.Q.e I, Buenos Aires, Argentina, 2F. Hoffmann-La
Roche AG, Basel, Switzerland
OBJECTIVES: Rituximab (RTX; MabThera) is available in
Argentina for the treatment of rheumatoid arthritis (RA) in
patients refractory to tumour necrosis factor (TNF) inhibition.
Evidence suggests that response to RTX is inﬂuenced by the
number of prior TNF inhibitors [1]. This study evaluates the
cost-beneﬁt ratio of current biologic therapies and determines
the cost-beneﬁt impact of introducing RTX following one or
more TNF inhibitors. METHODS: Prices were taken from three
different pharmacies, DroFar, Social Congresso, Scienza, Jan
2007 ($US1 = $ARS3.12; €1 = $ARS4.05). Average annual treat-
ment costs (drug treatment and administration) were determined
over a three year period. ACR20 response rate was chosen as the
measure of beneﬁt. Using pivotal trial data, unadjusted for dif-
ferent placebo response, the percentage of patients achieving an
ACR20 response rate was: RTX + MTX, 58%; INFL + MTX,
50%; ADAL + MTX, 63% and ETAN + MTX, 71%. ACR20
response rates for RTX were 58%, 51% and 42% after an
inadequate response to 1, 1.5 and 2 TNF inhibitors respectively.
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The cost-beneﬁt ratio was calculated as the cost per ACR20
response rate by dividing the average annual treatment cost by
the ACR response rate. RESULTS: In a cost-beneﬁt analysis,
RTX was found to have the lowest cost (in $ARS) per ACR20
response rate relative to current biologic therapies: RTX +
MTX = $58,577; INFL + MTX = $79,038; ADAL + MTX =
$83,035 and ETAN + MTX = $84,708. If RTX was introduced
following an inadequate response to 1.5 TNF inhibitors the
cost-beneﬁt ratio was $66,617 and this increased to $80,892
following 2 prior TNF inhibitors. CONCLUSION: These results
conﬁrm that, compared with current biologic agents RTX has the
superior cost-beneﬁt proﬁle. The cost-beneﬁt of RTX is maxi-
mised the earlier RTX is introduced, ie. following an inadequate
response to one prior TNF-inhibitor instead of two. [1] Kremer
JM, Tony HP, Tak PP et al. ACR 2006 (Abstract 0133).
PAR4
ASSOCIATION BETWEEN SWITCHING PATTERNS AMONG
ANTI-TUMOR NECROSIS FACTORS (ANTI-TNFS) AND
HEALTH CARE COSTS INTHETREATMENT OF
RHEUMATOID ARTHRITIS
Tang B1, Rahman MI1, Meissner B2, Dabbous O1,Thompson HC1
1Centocor, Inc, Horsham, PA, USA, 2Xcenda, LLC, Palm Harbor, FL,
USA
OBJECTIVES: To evaluate the relationship between switching
patterns among anti-TNFs and health care costs in rheumatoid
arthritis (RA) patients. METHODS: A retrospective study utiliz-
ing the PharMetrics managed-care claims database was con-
ducted. The ﬁrst anti-TNF encounter among RA patients
between January 1, 2001 and January 1, 2004 was identiﬁed.
Patients were required to have a minimum of 12-months of
continuous plan-eligibility prior to and following their index
date. RA-related health care costs were compared between two
mutually exclusive cohorts: patients who switched to another
anti-TNFs versus patients who did not switch. Descriptive and
Chi-square statistical analyses were conducted to determine if
differences existed between the two cohorts. Multivariate analy-
sis was performed to adjust for confounding factors. RESULTS:
In total, 2231 patients were analyzed. Over two-thirds of all
patients were female; the mean age was 50.2 years. The Charlson
Co-morbidity Index (CCI) and disease staging were similar
between the two cohorts. During the 12-month follow-up, 207
patients (9.3%) were switched from one anti-TNF to another.
The average time before switching was 187 days. Compared with
patients who did not switch, patients who switched had higher
total health care costs ($19,256 versus $16,753, P = 0.005), phy-
sician visits ($1350 versus $900, P < 0.0001), inpatient hospital-
izations ($1213 versus $899, P = 0.472), ER visits ($33 versus
$30, P = 866), pharmacy costs ($15,478 versus $13,445,
P = 0.001), except outpatient ($402 versus $509, P = 0.511) and
other costs ($704 versus $919, P = 0.598). After adjusting for
age, gender, CCI, and pre-index period health care costs, patients
who switched had signiﬁcantly higher total and medical costs
than patients who did not switch. CONCLUSION: The rate of
switching and time before switching are important measures of
the effectiveness of RA treatment in real world practice. This
study found that switching between anti-TNF therapies is asso-
ciated with higher health care costs.
PAR5
ADALIMUMAB, ETANERCEPT OR INFLIXIMAB:WHAT ISTHE
MOST COST-EFFECTIVE ANTI-TNF-áTHERAPY IN RA IN A
REAL-WORLD SETTING?
Deeg M1, Ekelund M2, Runge C1
1Wyeth Pharma GmbH, Münster, Germany, 2Wyeth AB, Solna,
Sweden
OBJECTIVES: In the past years anti-TNF-a drugs have become
a crucial component of the treatment of Rheumatoid Arthritis
(RA). Recent health-policy decisions prove that in Germany
initial choice of agents will increasingly depend on expected
treatment costs and cost-effectiveness. In order to inform deci-
sion making we assessed the cost-effectiveness of Adalimumab
(ADA), Etanercept (ETA), and Inﬂiximab (INF) based on pub-
lished real-world data from the German Biologics Registry.
METHODS: We designed an excel-based model and calculated
the costs per LUNDEX responder month. The LUNDEX score
developed by Kristensen et al. (2006) is combining the propor-
tion of patients fulﬁlling a response criterion (e.g. ACR 20) with
therapy adherence. Our model compares the costs per LUNDEX-
response over six months for the treatment with ADA, ETA and
INF from a payer-perspective. ACR 20 response rates after
six months (INF = 46%, ADA = 50%, ETA = 58%), therapy
adherence therapy (INF = 77%, ADA = 79%, ETA = 82%) and
real-world dosing data (INF = 4 mg/kg body weight, ADA =
40 mg/bw, ETA = 47.5 mg/week) were derived from published
registry data. Drug, administration and lab costs were calculated
using ofﬁcial databases. RESULTS: During the ﬁrst six months,
treatment with INF, ADA or ETA causes costs of 11,151€,
8,542€ and EUR 9,936€, respectively. The LUNDEX index at six
months is 0.357 for INF, 0.395 for ADA and 0.477 for ETA. The
costs per LUNDEX response are 21,626€ for ADA, 21,626€ for
ETA and 31,210€ for INF. The average cost per LUNDEX-
responder month in Germany is 3,901€ for ADA, 3,450€ for ETA
and 5,162€ for INF during the ﬁrst six months of treatment.
CONCLUSION: Our analysis supports decision making based
on a combined measure of response and therapy adherence.
According to German registry data ETA seems to be the most
cost-effective agent. Long-term data on response and adherence
are needed to further assess real-world cost-effectiveness of
TNF-therapy.
PAR6
A COST EFFECTIVENESS PRELIMINARY STUDY ON A NEW
TOTAL KNEE ARTHROPLASTY SYSTEM AND A PERIPHERAL
NERVE BLOCKADETECHNIQUE
Aguiar García F1, García Ruiz A2, Herrera Espiñeira C3,
Bertrand García M1, Fernández Gordillo F1, Guerado Parra E1
1Costa del Sol Hospital, Marbella, Málaga, Spain, 2Málaga University,
Málaga, Málaga, Spain, 3Hospital Virgen de las Nieves, Granada,
Granada, Spain
OBJECTIVES: Detect beneﬁts after a procedure modiﬁcations in
Total Knee Arthroplasty (TKA) via a pharmacoeconomic study.
METHODS: In November 2000–September 2006, 258 total
TKA were performed at our Hospital. Until January 2005,
Interax total knee system was used (Group A, 194 knees). Since
then, prostheses system was substituted to Triathlon and a
peripheral nerves blockade technique was implemented by the
anaesthetic staff in addition to usual epidural blockade (Group B,
64 knees). Patients were admitted the same day of the operation,
and discharged when absence of pain or effectively controlled
with oral medication, no bleeding or swelling of the wound, no
need for transfusion and patient agreement. Costs were measured
from a NHS perspective (direct and indirect sanitary costs) and
effectiveness determined in terms of hospital stay, pain, range of
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